| Buprenorphine (n = 14) | Methadone (n = 12) | Healthy control (n = 14) | Group or time point comparison p-values |
---|---|---|---|---|
Opioid agonist drug, dose | Â | Â | Â | Â |
Buprenorphine (M ± SD; (range) ) |  |  |  |  |
T1 | 16 ± 3 mg (12 - 24 mg) | - | - | - |
T2 | 20 ± 5 mg (14 - 28 mg) | - | - | T2 > T1** |
T3 Methadone (M ± SD;(range) ) | 21 ± 6 mg (6 - 28 mg) | - | - | T3 > T1** |
T1 | - | 71 ± 39 mg (30 - 135 mg) | - | - |
T2 | - | 127 ± 36 mg (80 - 180 mg) | - | T2 > T1 *** |
T3 | - | 135 ± 34 mg (75 - 180 mg) | - | T3 > T1 *** |
Participants treated with BZD medication | Â | Â | ' | Â |
T1 | 79% | 100% | 0% | BN & M > HC *** |
BZD dose at T1 (M ± SD) | 20 ± 17 mg | 21 ± 11 mg | - | ns a |
T2 | 71% | 100% | 0% | BN & M > HC *** |
BZD dose at T2 (M ± SD) | 16 ± 11 mg | 22 ± 11 mg | - | ns a |
T3 | 64% | 100% | 0% | BN & M > HC *** |
BZD dose at T3 (M ± SD) | 13 ± 12 mg | 22 ± 9. mg | - | BN < M * |
Number of other medications with possible cognitive effects b (M ± SD (range)) |  |  |  |  |
T1 | 1.9 ± 1.1 (0 - 4) | 3.0 ± 1.3 (0 - 5) | 0.2 ± 0.4 (0 - 1) | BN & M > HC ***; M > BN * |
T2 | 1.9 ± 1.2 (0 - 3) | 2.3 ± 0.8 (1 - 4) | 0.2 ± 0.4 (0 -1) | BN & M > HC *** |
T3 | 1.8 ± 1.3 (0 -4) | 2.2 ± 1.0 (1 -4) | 0.2 ± 0.4 (0 -1) | BN & M > HC *** |